Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate

[1]  Cardinale B. Smith,et al.  Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate—a post hoc analysis of a randomized clinical trial , 2020, Supportive Care in Cancer.

[2]  J. Eastham,et al.  Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Drake,et al.  The skeletal impact of cancer therapies. , 2019, British journal of clinical pharmacology.

[4]  D. Amadori,et al.  Ten-year experience of the multidisciplinary Osteoncology Center , 2019, Supportive Care in Cancer.

[5]  Janet E Brown,et al.  Metastatic bone disease: Pathogenesis and therapeutic options , 2018, Journal of bone oncology.

[6]  Mark S. Litwin,et al.  The Diagnosis and Treatment of Prostate Cancer: A Review , 2017, JAMA.

[7]  M. Terris,et al.  Factors predicting skeletal‐related events in patients with bone metastatic castration‐resistant prostate cancer , 2017, Cancer.

[8]  Yehui Chen,et al.  Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[9]  K. Ho,et al.  Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy. , 2015, Hong Kong medical journal = Xianggang yi xue za zhi.

[10]  K. Eguchi,et al.  Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR 13 , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  K. Izumi,et al.  Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal‐related events in patients with prostate cancer with bone metastasis , 2012, BJU international.

[12]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[13]  Janet E Brown,et al.  Prognostic factors for skeletal complications from metastatic bone disease in breast cancer , 2010, Breast Cancer Research and Treatment.

[14]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[15]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[16]  F. Saygili,et al.  Causes of High Bone Alkaline Phosphatase , 2007 .

[17]  L. Dogliotti,et al.  Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease , 2005, British Journal of Cancer.

[18]  D. Finkelstein,et al.  Predictors of skeletal complications in patients with metastatic breast carcinoma , 2000, Cancer.

[19]  M. Broder,et al.  Burden of skeletal-related events in prostate cancer: unmet need in pain improvement , 2014, Supportive Care in Cancer.